Exact Sciences Corporation
General ticker "EXAS" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $10.0B (TTM average)
Exact Sciences Corporation follows the US Stock Market performance with the rate: 43.4%.
Estimated limits based on current volatility of 0.1%: low 102.27$, high 102.53$
Factors to consider:
- Total employees count: 7000 as of 2024
- US accounted for 93.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Lack of profitability, Market competition, Operational and conduct risks, Senior management dependency, Liquidity and credit risks
- Current price 32.6% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [42.14$, 83.69$]
- 2025-12-31 to 2026-12-31 estimated range: [38.23$, 77.27$]
Financial Metrics affecting the EXAS estimates:
- Negative: with PPE of -66.8 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Positive: 19.35 < Shareholder equity ratio, % of 40.52 <= 42.53
- Positive: Industry inventory ratio change (median), % of -0.84 <= -0.18
Short-term EXAS quotes
Long-term EXAS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2,071.03MM | $2,578.19MM | $2,758.87MM |
| Operating Expenses | $2,664.55MM | $2,793.20MM | $3,807.57MM |
| Operating Income | $-593.51MM | $-215.01MM | $-1,048.70MM |
| Non-Operating Income | $-39.06MM | $13.27MM | $12.54MM |
| Interest Expense | $19.63MM | $19.45MM | $31.97MM |
| R&D Expense | $393.42MM | $425.88MM | $431.21MM |
| Income(Loss) | $-632.57MM | $-201.75MM | $-1,036.16MM |
| Taxes | $-9.06MM | $2.40MM | $-7.30MM |
| Profit(Loss)* | $-623.51MM | $-204.15MM | $-1,028.86MM |
| Stockholders Equity | $3,043.16MM | $3,145.30MM | $2,402.25MM |
| Inventory | $118.26MM | $127.47MM | $162.38MM |
| Assets | $6,226.87MM | $6,471.33MM | $5,928.14MM |
| Operating Cash Flow | $-223.56MM | $156.12MM | $210.54MM |
| Capital expenditure | $214.46MM | $124.19MM | $135.99MM |
| Investing Cash Flow | $74.07MM | $49.68MM | $-442.15MM |
| Financing Cash Flow | $76.48MM | $159.77MM | $231.87MM |
| Earnings Per Share** | $-3.54 | $-1.13 | $-5.59 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.